Is Amgen Stock a Buy?
Now more than ever, investors are searching for reliable stocks with a solid financial history, strong potential for long-term growth, and a decent dividend payout. As was the case with many other stocks in the broader market, Amgen (NASDAQ: AMGN) fell sharply in March. Shares started moving toward recovery in early April, and are currently lagging just about 7% behind the stock's 52-week high.
The company since reported an 11% increase in revenue in the first quarter of 2020, and projects 2020 revenue to be anywhere from $25 billion to $25.6 billion, which is consistent with its full-year guidance entered before the pandemic started. If you're thinking about buying this stock, here's what you need to know.
Image source: Getty Images.
Source Fool.com
